Chapter 123: Tianmu Eye Drops

The intelligent driving trend has swept the globe, leaving automakers in every country restless.

They secretly mobilized their influence to strike at the reputation of the Xiaozhi Driving System, not because they looked down on it, and certainly not because they truly intended to oppose it.

It was simply because they did not have it in their own hands.

Grapes one cannot reach are, of course, sour.

In reality, the major automakers had long been coveting the Xiaozhi Driving System.

Now, since the suppression campaign had been declared a total failure, the momentum of the Xiaozhi Driving System had only grown, becoming increasingly popular with users.

Tianqi Equipment Company had put out the word again that they would select five partners within two months.

Naturally, there was no need for them to try and suppress the Xiaozhi Driving System anymore; instead, they had to find a way to secure a spot as one of these five partners.

However, for every country or region, Tianqi Equipment would only select one partner enterprise...

Thinking of this.

Automakers from various countries felt unwilling to accept it.

On one hand, they felt that as top-tier global automakers, they could not be easily manipulated by Tianqi Equipment.

On the other hand, they were somewhat worried that if they did not strive with all their might, the partnership qualification would be snatched away by other automakers, and they would only be able to watch as their competitors leveraged the advantages of the Xiaozhi Driving System to leave them far behind in terms of popularity and sales.

By then, it would be too late for regrets.

Consequently, the senior management of automakers from various countries agreed to hold a joint meeting, righteously claiming they must stand united, move forward and retreat together, and absolutely must not let Tianqi Equipment Company manipulate them.

After the meeting, the senior management of each automaker actively contacted Tianqi Equipment Company to submit a request for partnership on the Xiaozhi Driving System.

While the major automakers were seeking cooperation with Tianqi Equipment Company, the high-level officials of various countries were also solemnly discussing policies related to intelligent driving.

Long Country, Tianjing City.

Inside a Biology Laboratory.

Su Xin had been keeping a low profile here in seclusion for about half a month; every day, besides eating and sleeping, he studied the refractive system of the human eye, attempting to stimulate the human eye to self-regulate through various methods.

After verifying dozens of highly feasible plans, Su Xin finally developed a brand-new biomedical technology.

It utilizes a biological agent, processed through several stages using the metabolic products of a certain microorganism at an appropriate temperature, to stimulate the eyeball, making the refractive system within the eye more active and possessing greater room for self-adjustment.

Supplemented by appropriate eye massage, it prompts the axial length of the human eye to contract or elongate, thereby achieving the effect of treating myopia or hyperopia.

Actually.

This myopia correction technology is not much more difficult than the technology for Artificial Intelligence or the Solid-state Battery.

The reason it took a full half-month this time was mainly because there was no guidance from predecessors; he had no specific research direction and could only keep trying on different paths.

Unlike when he was developing the Tiantian Assistant and the Thor Battery, where the industry had basically explored the optimal direction, leaving only the need for specific solutions.

Therefore, Su Xin only needed to follow the path pointed out by industry insiders and stride forward.

But this time, basically no one was researching myopia correction technology from a biological perspective like he was.

Everything had to be explored by himself.

Fortunately, he succeeded!

However, although the biological agent he had developed now had perfect effects and no side effects, it could only be considered a laboratory product, not the final finished medicine.

In the actual mass production process, some excipients still needed to be added.

For example, culture media and supplements to maintain the survival of the microorganisms and increase the shelf life of the medicine; in addition, there are freeze-drying protectants to prevent damage during refrigerated transport, bactericides to avoid bacterial growth, stabilizers to prevent the aggregation of active substances, and adjuvants to aid absorption, etc.

These various excipients must neither affect human health nor interfere with the efficacy of the medicine, and they certainly must not react with each other to produce new substances.

Su Xin recorded the technical data of the biological agent in detail and named it Tianmu Eye Drops.

Afterward, he began researching various combinations of excipients.

Until evening.

He put together over thirty different excipient formulas, adding them separately into over thirty reagent bottles containing the biological agent, and stored them in refrigeration.

Next, he only needed to wait calmly for about a week, then observe which reagent bottle had the best-preserved biological agent, and he would be able to test and select the most suitable excipient formula from among them.

By then, the Tianmu Eye Drops would be considered officially developed.

When Su Xin walked out of the Laboratory, it was already past seven in the evening; the sky outside was already quite dim, and the colorful neon lights adorned the outline of the distant city beautifully.

He got into the car waiting outside the door, and the bodyguard Wang Zhao immediately ordered the vehicle to start.

As the creator of the intelligent driving solution, Su Xin naturally had to support his own technology, so as early as when the major automakers began mass production, he had replaced all the vehicles under his company's name with intelligent driving models from Long Country.

Sitting in the car.

Su Xin dialed a phone call to Liu Xuewei.

"Xuewei, I'm off work."

On the other end of the line, Liu Xuewei was wearing an apron, her cheeks rosy, holding the phone with a charming smile:

"Okay, I made the steamed pork with rice flour you love; hurry back and have a taste."

Ever since Su Xin visited her home during the New Year, their relationship had been completely settled, and they had moved in together this year.

Since her work was not very busy, she occasionally learned to cook at home after work; fortunately, she was quite talented, and the dishes she made following various tutorials tasted pretty good.

About an hour later, Su Xin returned home, finished dinner with Liu Xuewei, and sat on the sofa chatting while embracing.

"By the way, I already signed the employment agreement with Nie Hongwu today; he will officially start tomorrow. Do you want to find some time to meet him?"

Nie Hongwu was the newly recruited pharmaceutical company executive, and also the sixth executive of Tianqi Company.

Hearing this, Su Xin nodded:

"That's perfect; my new medicine is also about finished in development. Once he starts, I can have him follow up on the drug approval work."

"So fast?"

Liu Xuewei looked at him with a face full of surprise.

Su Xin grinned: "Of course, it's just a simple myopia correction technology; in the field of biomedicine, it only counts as entry-level."

In fact, this technology indeed only counts as entry-level in Su Xin's view; currently, it can only stimulate the eyes to allow the refractive system to self-regulate and recover, thereby treating myopia and hyperopia.

He has even further research goals.

On the basis of the self-regulation and recovery of the intraocular refractive system, he aims to further increase the adjustment range to achieve the goal of enhancing visual range.

The technical directions of the two seem completely identical, but the difficulty between them is as vast as heaven and earth.

If one compares the process of Tianmu Eye Drops correcting myopia to the recovery of an injury on the body, it only requires stimulating physical growth and healing, something many drugs can achieve.

Then, the technology for enhancing visual range is equivalent to performing physical enhancement on the basis of injury recovery; currently, no drug in the entire world can achieve this.

The disparity is clearly immense.

Su Xin developed Tianmu Eye Drops, but he still has not made much progress on visual range enhancement.

Therefore, after he releases Tianmu Eye Drops next, he will also devote more time to the further research and development of this drug.